- Title
- TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
- Creators
- Ritu SalaniLin ZhongqiuShin NishioAna OakninJean-Emmanuel KurtzGiorgio ValabregaStefania CanovaM. Valeria CáceresPhilipp HarterLucy GilbertAzmat H. SadozyeLilian Arruda Do Rêgo BarrosJung-Yun LeeToon Van GorpIngrid BoereChristian MarthRadosław MądryFlora ZagouriLinda DuskaBradley MonkXin Tong LiAgata M. BoguszSarper TokerKristina Lindemann
- Publication Details
- International journal of gynecological cancer, Vol.35(11), p.102609
- Identifiers
- 991006233228502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
International journal of gynecological cancer, Vol.35(11), p.102609
11/2025
Metrics
2 Record Views